miRNA MARKER FOR DIAGNOSIS AND/OR TREATMENT OF ALZHEIMER'S DISEASE
The disclosure provides a miRNA marker for the treatment and/or diagnosis of Alzheimer's disease (AD), and the miRNA marker is a miRNA23 cluster. The disclosure provides use of the miRNA23 cluster in the diagnosis and treatment of AD. The expression of the miRNA23 cluster is detected using primers for the microRNA marker through AD model cells, AD model animals and natural aging animals, and blood of AD patients, and it is found that the expression of the miRNA23 cluster is significantly reduced during the progression of AD, which reduces neuronal apoptosis by inhibiting the GSK-3β-mediated tau protein phosphorylation. Therefore, the miRNA23 cluster can be used as a novel biomarker and therapeutic target for the early, non-invasive diagnosis and treatment of AD.
1 .- 22 . (canceled)
23 . Use of an agonist for a miRNA marker in the preparation of a medicament for treating AD, wherein the miRNA marker is a miRNA23 cluster; and the miRNA23 cluster is hsa-miR-23b, with a nucleotide sequence shown in SEQ ID NO. 1; or the miRNA23 cluster is hsa-miR-23b-3p, with a nucleotide sequence shown in SEQ ID NO. 2.
24 . Use of a primer in the preparation of a kit, wherein, the primer is a primer specific for the miRNA marker according to claim 23 .
25 . The use according to claim 24 , wherein, the kit is used to diagnose AD, predict the risk of developing AD, or predict the outcome of AD in patients suffering from or at risk of developing AD.
26 . The use according to claim 24 , wherein the primer is used to determine the expression level of the miRNA marker in a sample.
27 . The use according to claim 26 , wherein the sample is serum.
28 . The use according to claim 26 , wherein, the expression level of the miRNA marker is based on the expression level of the miRNA marker in a patient and the reference expression level of the miRNA marker in a healthy subject.
29 . The use according to claim 28 , wherein, the expression level of the miRNA marker is determined by a sequencing-based method, an array-based method, or a PCR-based method.
30 . The use according to claim 28 , wherein, the expression level of the miRNA marker is determined by a sequencing-based method, an array-based method, or a PCR-based method.